NasdaqGS:BNTXBiotechs
BioNTech Board Expansion Signals Focus On Oncology Execution And Valuation Gap
BioNTech (NasdaqGS:BNTX) has expanded its Supervisory Board following major late stage oncology data announcements at ASCO 2026.
Prof. Iris Löw-Friedrich and Dr. Susanne Schaffert have been elected, adding experience in clinical development, oncology, and international commercialization.
The board changes are described as aligning with BioNTech’s push to advance multiple pivotal cancer trials and prepare for potential future product launches.
BioNTech, known for its mRNA technology...